On the other hand, treatment with human ApoA1 in a transgenic model of Alzheimer’s disease reduced amyloid accumulation, brain neuronal loss, and neuroinflammatory response, and improved cognitive function [68,72]. Here, APOA1 is linked to early-onset autosomal dominant Alzheimer disease.